DRUG
Methotrexate
Drugs to treat undisturbed ectopic pregnancies
The Aromatase Inhibitor and Gnrh Antagonist Versus Methotrexate for Management of Undisturbed Ectopic Pregnancy
Status
Unknown
Phase
Not applicable
Enrollment
120
Locations
0
Results
Not posted
Publications
0
Study summary
What the protocol is testing.
The aim of this study is to : 1. Use of the aromatase inhibitor( letrozole) for the treatment of ectopic pregnancy compared to methotrexate. 2. Use of the Gnrh antagonist for the treatment of ectopic pregnancy compared to methotrexate.
Interventions
Treatment arms and agents.
DRUG
Letrozole
Drugs to treat undisturbed ectopic pregnancies
DRUG
cetrotide
Drugs to treat undisturbed ectopic pregnancies
Timeline
From registration to results.
First posted
Mar 16, 2020
Study start
Mar 30, 2020
Primary completion
Mar 1, 2022
Study completion
Sep 1, 2022
Results posted
Not reported
Registry updated
Mar 16, 2020
Outcomes
What the study measures.
Primary outcomes
determine efficacy of the aromatase inhibitor and Gnrh antagonist to achievement of resolution of ectopic pregnancy determined by serum hCG levels below laboratory immunoassay detection <15 IU/l.Results will be statistically analyzed,then evaluated .
Time frame · 3 months
Secondary outcomes
Not reported in the indexed record.
Eligibility
Who can take part.
- Minimum age
- 18 Years
- Maximum age
- 40 Years
- Sex
- FEMALE
- Healthy volunteers
- No
Inclusion Criteria: * Patients who have undisturbed ectopic pregnancy .Who are: 1. have no significant pain 2. have an unruptured tubal ectopic pregnancy with an adnexal mass smaller than 35mm with no visible heartbeat 3. have a serum human chorionic gonadotropins level less than 1,500 IU/litre 4. do not have an intrauterine pregnancy (as confirmed on an ultrasound scan) . Exclusion Criteria: 1. An undisturbed ectopic pregnancy and significant pain 2. An undisturbed ectopic pregnancy with an adnexal mass of 35 mm or larger 3. An undisturbed ectopic pregnancy with a fetal heartbeat visible on an ultrasound scan 4. An undisturbed ectopic pregnancy and a serum human chorionic gonadotropins level of 5,000 IU/litre or more 5. intrauterine pregnancy
Study locations
0 registered sites.
No country data reported. Showing up to 24 locations stored in the fast local snapshot.
No study locations reported.
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Cetrorelix.
NCT IDStudyPhase / statusEnrollmentUpdated
Drospirenone-Primed Ovarian Stimulation Versus GnRH Antagonist Protocol in Poor Ovarian Responders Undergoing Freeze-All IVF/ICSI
Ahmed Saad · Poor Ovarian Reserve · Infertility (IVF Patients)
Phase 1 / Phase 2
Not yet recruiting
100
2026-07
Oral GnRH Antagonist (Linzagolix) Versus Injectable GnRH Antagonist for Ovarian Stimulation in IVF/ICSI
Centro A.M.B.R.A. (Associazione Medici e Biologi per la Riproduzione Assistita) · Infertility, Female · Ovulation Induction
Early Phase 1
Not yet recruiting
189
2026-07
A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA)
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · Infertility
Phase 3
Recruiting
266
2026-07
Serum FSH Monitoring for Identification of an Optimal Range During Ovarian Stimulation
ART Fertility Clinics LLC · Ovarian Stimulation
Not applicable
Recruiting
150
2026-06
Dydrogesterone Versus GnRH Antagonist in Poor Responders Undergoing Double Ovarian Stimulation
Bedaya Hospital · Infertility
Phase 2
Recruiting
120
2026-05
Progesterone Primed Protocol Versus GnRH Antagonist in With PCO Undergoing ICSI
Beni-Suef University · IVF · PCO
Phase 2 / Phase 3
Completed
200
2026-04
NATural Ovarian Stimulation
Assistance Publique - Hôpitaux de Paris · Infertility
Phase 4
Completed
129
2026-04
Preservation of Fertility by Ovarian Stimulation Associated With Tamoxifen, Prior Chemotherapy for Breast Cancer
Institut Cancerologie de l'Ouest · Breast Cancer
Phase 2
Active, not recruiting
102
2026-03
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.